Associated tags: Health, EUR, Patient, Achondroplasia, CFO, ACH, European, Osteochondrodysplasia, PTH, Endocrinology, Phase II, Pharmaceutical industry
Locations: ISTANBUL, TR, RARE, EUROPEAN UNION, ROMANIA, CROATIA, MONTENEGRO, CYPRUS, BULGARIA, HUNGARY, ESTONIA, KOSOVO, CENTRAL, LITHUANIA, SLOVAKIA, GREECE, LATVIA, SERBIA, POLAND, SLOVENIA, MALTA, ALBANIA
ATHENS, Greece, March 05, 2024 (GLOBE NEWSWIRE) -- Er-Kim , a pharmaceutical company specializing in the commercialization of novel therapies in international markets, announced today it has been selected to join the World Economic Forum’s New Champions Community, a group of dynamic forward-looking companies that are championing new business models, emerging technologies, and sustainable growth strategies.
Key Points:
- ATHENS, Greece, March 05, 2024 (GLOBE NEWSWIRE) -- Er-Kim , a pharmaceutical company specializing in the commercialization of novel therapies in international markets, announced today it has been selected to join the World Economic Forum’s New Champions Community, a group of dynamic forward-looking companies that are championing new business models, emerging technologies, and sustainable growth strategies.
- Er-Kim will also be the first company from the Central & Eastern Europe region to join this community.
- “It is an honor to be part of a group encompassing different sectors of society so highly committed to improving the state of our world,” said Mert Zorlular, Er-Kim Chairman.
- “We believe the opportunity to join a global community of like-minded purpose-driven peers will help support increasing our impact on addressing healthcare inequity, responding to increasing rates of antimicrobial resistance and championing responsible use of Artificial Intelligence in the service of patients.”
Julia Devos, Head of the New Champions, added, "We are thrilled to welcome Er-Kim to our New Champions community at the World Economic Forum.
BUCHAREST, Romania, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Er-Kim , an international pharmaceutical company specializing in the commercialization of novel therapies, today announced it has entered into an exclusive distribution agreement with Danish Company Ascendis Pharma A/S (Nasdaq: ASND) for its endocrinology portfolio.
Key Points:
- BUCHAREST, Romania, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Er-Kim , an international pharmaceutical company specializing in the commercialization of novel therapies, today announced it has entered into an exclusive distribution agreement with Danish Company Ascendis Pharma A/S (Nasdaq: ASND) for its endocrinology portfolio.
- Under the agreement, Er-Kim is appointed as the exclusive Ascendis A/S endocrinology distributor in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czechia, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, Malta, Montenegro, North Macedonia, Poland, Romania, Serbia, Slovakia, Slovenia, and Türkiye.
- He added, “Leveraging our exceptional expertise in rare diseases and our preeminent status in endocrinology throughout the region, we eagerly anticipate collaborating with Ascendis and the healthcare community.
- “We are therefore very pleased to partner with Er-Kim, a company that shares this commitment, to broaden and accelerate access to our innovative Endocrinology Rare Disease treatment options across Central and Eastern Europe and Turkey.”
Retrieved on:
Thursday, October 15, 2020
Under the terms of the agreement, Er-Kim will have the exclusive rights to commercialize Collategene in Turkey after obtaining the necessary regulatory approvals.
Key Points:
- Under the terms of the agreement, Er-Kim will have the exclusive rights to commercialize Collategene in Turkey after obtaining the necessary regulatory approvals.
- After the approval of the product, Er-Kim will be responsible for sales, marketing and local medical affairs activities as it relates to Collategene.
- Moreover, AnGes and Er-Kim will make Collategene immediately available through Named Patient Program* prior to approval.
- Ei Yamada, President and CEO of AnGes commented, This collaboration will further expand the geographical reach of our product and provide new treatment options for patients in Turkey.
